μια πρωτοβουλία της IPSEN IPSEN LOGO
Αυτές οι πληροφορίες προορίζονται για γενική πληροφόρηση και ενημέρωση του κοινού και σε καμία περίπτωση δεν μπορούν να υποκαταστήσουν την συμβουλή ιατρού ή άλλου αρμόδιου επαγγελματία υγείας.

1. Canadian Cancer Society. The neuroendocrine system. Accessed May 22, 2019.
2. Sackstein PE, O’Neil DS, Neugut AI, et al. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Seminars in Oncol. 2018;4(13):249–58.
3. Ramirez RA, Chauhan A, Gimenez J, et al. Management of pulmonary neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18(4):433-442.
4. National Cancer Institute. Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)-Patient Version. 2018. Accessed October 22, 2018.
5. National Cancer Institute. Pheochromocytoma and paraganglioma treatment (PDQ®)-patient version. 2017. Accessed October 23, 2018.
6. Schernthaner-Reiter MH, Trivellin G, Stratakis CA. MEN1, MEN4, and Carney complex: pathology and molecular genetics. Neuroendocrinology. 2016;103: 18e31.
7. Cancer.NET Editorial Board. Neuroendocrine Tumor of the Pancreas: Symptoms and Signs. 2017. Accessed October 22, 2018.
8. Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;2(1):43–53.
9. National Institute of Diabetes and Digestive and Kidney Diseases. Your digestive system and how it works. Accessed October 19, 2018.
10. Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. 2006; 4(5): 526-47, 2006.

Log in with your credentials

Forgot your details?